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Background: Physical activity is frequently reported in rheumatology but it is difﬁcult to measure objectively out-
side the gait laboratory. A newgeneration of activitymonitors offers this potential but it has not yet been evaluated
in patientswith rheumatoid arthritis. This study aimed to evaluate three types of activitymonitors in patientswith
rheumatoid arthritis.
Methods: The Step-N-Tune, Activ4Life Pro V3.8, and the Intelligent Device for Energy Expenditure and Activity activ-
ity monitors were tested concurrently in 12 patients with rheumatoid arthritis as well as in a healthy control group
of 12 volunteers. Participantswalked at a self selected speed for twominutes andwereﬁlmed for later review. Tem-
poral and spatial gait parameters were also validated against the GAITRite walkway and the total number of steps
recorded by each activity monitor was compared to a gold standard derived from half speed video replays.
Findings: Activity monitor performance varied between devices but all showed poorer performance when used in
the group with rheumatoid arthritis. Bland–Altman plots demonstrated wider 95% limits of agreement in the
group with rheumatoid arthritis and a systematic decrease in agreement between activity monitors and the
gold standard with decreasing functional ability.
Interpretation:Despite some variation between devices, all the activitymonitors tested performed reasonablywell
in healthy young volunteers. All except the Activ4Life showed a marked decrease in performance in patients with
rheumatoid arthritis, suggesting Activ4Life could be the most suitable for use in this patient group. The marked
between group difference in functional ability, and systematic decrease in device performance with deteriorating
gait, indicate that activity monitors require speciﬁc validation in target clinical populations.© 2013 Elsevier Ltd. All rights reserved.1. Introduction
Functional ability and physical activity have traditionally been used
as outcomemeasures in studies investigating the impact of interventions
on physical function. More recently, advances in the management of
rheumatoid arthritis (RA) have placed greater importance on associated
co-morbidities and their impact on patients (Avina-Zubieta et al., 2012).
In particular, cardiovascular risk is elevated in patients with RA, in part
due to physical inactivity and the majority of patients fail to achieve
recommended activity levels (Cooney et al., 2011; Elkan et al., 2011;
van den Berg et al., 2007). Physical activity is therefore not only an
important outcome measure in therapeutic studies, but it can also be
an important therapeutic intervention in its own right. Physical activity66 from Arthritis Research UK.
usculoskeletal Disease, Chapel
ckhouse).
rights reserved.is difﬁcult to measure in community dwelling populations however, as
direct observation is often not feasible (Lee et al., 2009).
Subjective measures of activity, such as self reported questionnaires,
are widely used in epidemiological studies of healthy and clinical popu-
lations, including those with musculoskeletal disease (Bilek et al., 2005;
Lee et al., 2009). Concerns have been expressed however that they
underestimate low intensity and unstructured activities (Jacobs et al.,
1993; Kriska and Caspersen, 1997). This may be particularly problematic
in demographic groups such as older adults, many of whom acquire
most of their activity through low-intensity physical activities and
activities of daily living (Lee et al., 2009). Furthermore, self reported
activity questionnaires are also prone to the same limitations as
other subjective outcome measures, including phase shift and response
bias (e.g. imprecise recall and social desirability) (Coughlin, 1990;
Durante and Ainsworth, 1996). Again, recall bias appears to be highest
in low-intensity activities that are habitual (e.g. walking and housework)
rather than high intensity activities that are structured (e.g. sports), so
this would be a particular concern in a population of patients with RA
(Durante and Ainsworth, 1996). It is often recommended therefore, that
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ical activity (Lee et al., 2009).
Traditional laboratory basedmeasures of physical function and activ-
ity such as gait velocity, cadence and single/double support periods are
widely used and well validated in RA (Helliwell et al., 2007; Semple et
al., 2007; Turner andWoodburn, 2008). They are of limited use however,
in that it is not usually possible to record data outside of the artiﬁcial
environment of the gait laboratory. Devices such as pedometers and a
new generation of accelerometer based activity monitors offer the
potential to measure global activity in community dwelling populations.
Most validation has been undertaken in only healthy populations
however (Lee et al., 2009; Zhang et al., 2003, 2004). Despite this, concerns
have already been raised about the ability of bi-axial accelerometers to
detect acceleration in the transverse plane, leading to under-reporting
of activity in healthy volunteers with adducted or abducted feet
(Mafﬁuletti et al., 2008). To date, the validity of such activity monitors
in patients with RA, who often have marked gait abnormalities, has not
been assessed.
This study aimed to evaluate the concurrent validity of three types
of activity monitors in patients with rheumatoid arthritis.
2. Methods
2.1. Activity monitors
Activitymonitors were selected to represent three levels of complex-
ity: ﬁrst, a simple pedometerwith a springmounted lever arm; second, a
waist mounted device consisting of a single tri-axial accelerometer with
step counts derived from on board software; third, a device consisting of
multiple accelerometers able to measure additional data such as tempo-
ral and spatial gait parameters.
2.1.1. Step-N-Tune Pedometer, Kinergy Electronics Co., Ltd (Shenzhen, Hong
Kong, China)
The Step-N-Tune is a simple, inexpensive battery operated device
worn at the waist. Vertical forces at heel strike cause movement of a
spring mounted lever arm which opens and closes an electrical circuit
to register a step. The cumulative number of steps is then displayed
on an LCD screen on the device.
2.1.2. Activ4LifeProV3.8, Activ4LifeHealthcareTechnologies Ltd (Boroughbridge,
UK)
The Activ4Life (A4L) device comprises a small activity monitor
(38 × 32 × 10 mm) that is attached to the patient's skin and an associ-
ated docking station. The activity monitor, consisting of a single tri-axial
accelerometer, is worn during the day and then placed in the docking
station at night where data are downloaded and the activity monitor is
charged. Step counts are derived from actuation of the accelerometer
and proprietary onboard algorithms to identify patterns that correspond
to steps rather than other forms of activity such as driving. Data are then
uploaded to the company's servers usingmobile phone technology. Here
data are processed and then made available for clinicians to view by
logging on to a secure website. Total step counts are provided over a
24 h period and can be subdivided into ‘high intensity’ and ‘low intensi-
ty’ activities. Although the manufacturers performed 104 tests on the
device during its development, no results are available publically.
2.1.3. Intelligent Device for Energy Expenditure and Activity (IDEEA),
MiniSun LLC (Fresno, California, USA)
The IDEEA is an accelerometer based activity monitor consisting of
ﬁve skin-mounted bi-axial accelerometers and a 32-bit, 25 MHz
micro processor unit. Two sensors are mounted to the plantar surface
of the participant's feet, two on the anterior thigh, and the remaining
sensor attached over the sternum. Each sensor is connected via wires
to the small (70 × 44 × 18 mm) processor unit that is attached to the
participant's belt. Up to 200 MB can be stored on the device allowingit to collect data for up to 7 days, which is then uploaded to a PC for
processing and analysis. The location of sensors allows the device to
estimate the orientation of different body segments, thus enabling
posture and body movements to be identiﬁed as well as calculating
energy expenditure. In addition to a simple step count the IDEEA
also claims to be able to measure a number of temporal and spatial
gait parameters such as gait velocity and double support time.
The IDEEA is the only device used in this study that has previously
been validated in the literature. Previous studies have evaluated the
IDEEA's concurrent validity, conﬁrming that the device is able to
discriminate between 32 common physical activities and the energy
expenditure calculations have also been validated using direct and indi-
rect calorimetry (Zhang et al., 2003, 2004). These studies were however
conducted on younghealthy volunteers (mean age 34 and 36 years) and
involved periods of vigorous exercise so it was not clear if these results
can be generalised to RA patients performing low intensity activities.
2.2. Participants
Consecutive assenting patients were recruited from rheumatology
outpatient clinics. All patients with a consultant diagnosis of RA were
invited to participate except those who received intra-articular injec-
tions on the day, or had a current foot ulcer.Walking aidswere permitted
as required.
A group of healthy controls was recruited from staff and students of
the hospital and university department. Volunteers were eligible to par-
ticipate if they could walk freely for two minutes without pain and had
no known medical conditions affecting their gait. Eligibility was con-
ﬁrmed through history taking. Ethical approval was obtained from the
Leeds West Research Ethics Committee (08/H1307/65) and all partici-
pants provided written informed consent. All aspects of the study were
conducted in accordance with the Declaration of Helsinki.
2.3. Data collection
Activity monitors were mounted concurrently on the participants
according to the manufacturer's instructions as shown in Fig. 1. The
ﬁve sensors of the IDEEA were held in place using Medipore tape with
the processor unit attached to the waistband of the participants' shorts.
Loose wires were attached to the skin around the medial malleolus and
medial proximal quarter of the tibia and the participants wore socks to
prevent the plantar foot sensor catching the ﬂoor during gait (see
Fig. 1). The Step-N-Tune pedometer was fastened to the waistband on
the opposite hip and the participants attached the A4L device using the
double sided adhesive pads provided by the manufacturer. Prior to
attaching the device, the participants were provided with instructions
by the researcher. All devices were reset and care was taken to prevent
any unnecessarymovement or additional steps once theywere attached.
Following attachment of all devices, the participants sat on an
adjustable chair that was adjusted to allow positioning of the hips
and knees to 90° for calibration of the IDEEA device.
Temporal and spatial gait parameters recorded by the IDEEAwere
validated against a GAITRite instrumented walkway which has
previously been found to be highly reliable in the test population
(Menz et al., 2004; Rome, 2005). The participants rose from the
chair after the attachment of the activity monitors and walked
along the GAITRite walkway before sitting on a second chair posi-
tioned at the end of the walkway. Chairs were carefully positioned
to ensure that all steps during this stage took place on the
instrumented area of the walkway and that no additional steps
were required for the patients to get into position prior to sitting
on the chair. After pausing for ten seconds, the participants stood
and undertook a continuous walk around the gait laboratory for a
two minute period before returning to the chair. Throughout the
test period, the participants were followed by a member of the re-
search team (DW) who ﬁlmed the test procedure.
Fig. 1. Experimental setup of activity monitors. A: IDEEA; B: Step-N-Tune; C: Activ4Life
(attached directly to skin).
Table 1
Group mean step counts for each measure.
Measure Control group
Mean (SD)
RA patients
Mean (SD)
Gold standard 221.75 (19.21) 159.50 (38.65)
Step-N-Tune 213.75 (57.42) 86.27 (77.57)
A4L 247.17 (21.68) 177.27 (58.04)
IDEEA 184.67 (61.49) 72.92 (69.65)
Values indicate group average for each measure. Gold standard: mean of 3 counts from
half speed video replay; A4L: Activ4Life; SD: standard deviation.
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To establish a gold standard step count, a mean value was derived
from three manual counts of half-speed video replays. For the temporal
and spatial parameters of gait simultaneously recorded by the GAITRite
walkway and IDEEA, the GAITRite outputs were used as the gold
standard as this system has been shown previously to be valid and
reliable (Menz et al., 2004).
Raw data from the Step-N-Tune and A4L devices are presented di-
rectly as step counts and so required no further processing. GAITRite
data were processed and analysed using the GAITRite v3.8 software
(CIR Systems Inc., Sparta, New Jersey, USA).
For the IDEEA device, postural changes recorded when the partici-
pants sat on the two chairs provided discrete markers on the outputs
withwhich to analyse subsections of the IDEEA outputwithin the propri-
etary ActiView analysis software (MiniSun LLC, Fresno, California, USA).
The two sitting events discretely bookended the section of gait along
theGAITRitewalkway, allowing separate validation of temporal and spa-
tial gait parameters, in addition to the total step count of the full assess-
ment period.
2.5. Statistical analysis
Summary statistics were used to describe demographic and clinical
features of the participants.
Agreement between the activity monitors and gold-standard
measures was assessed using Bland–Altman plots. The familiar method
of calculating the 95% limits of agreement assumes that the mean and
standard deviation (SD) of the differences between two methods are
constant, irrespective of the magnitude of the measurements. Whena non-uniform relationship between difference and magnitude is
identiﬁed, Bland and Altman have proposed an alternative approach
using linear regression. For a given magnitude of measurement, the
mean difference between the measurement methods can be obtained
from the constant and slope of the regression line, whilst the 95% limits
of agreement are obtained from the SD of the residuals (Bland and
Altman, 1999; Kirkwood and Sterne, 2006). Formally the mean
difference is D^ ¼ b0 þ b1A where A is the estimate of the true value
of measurement, and the 95% limits of agreement are calculated as
D^  1:96 ﬃﬃﬃﬃﬃﬃﬃﬃπ=2p R^ where R^ represents the residual SD from the regres-
sion. Statistical analyses were conducted using PASW 18.0.0.
3. Results
3.1. Participants' proﬁle
The validation sample consisted of 24 participants (12 patients with
RA and 12 healthy volunteers). Within the RA group, 10 were female;
the group had a mean age of 51.6 years (SD = 18.0), and a mean BMI
of 31.1 (SD = 7.1). In the RA group the mean disease duration was
18 years (SD = 13.4), and median DAS28 and HAQ were 5.02
(IQR = 3.76 to 5.75) and 1.5 (IQR = 1.0 to 2.13) respectively. Half of
the control group were female (n = 6); the mean age was 41.6 years
(SD = 9.8), andmean BMIwas 23.4 (SD = 2.8). Although all the partic-
ipants walked for the same period of time, patients with RA took fewer
steps regardless of the method of counting used, as is seen in Table 1.
With the exception of the gold standards of video step count and
GAITRite, all four of the test devices malfunctioned at least once during
the study and in each case this did not become evident until the end of
thewalk or data processing. TheA4L and Step-N-Tune failed once,where-
as the IDEEA failed on three occasions.When devices failed, the automat-
ed step counts (IDEEA, Step-N-Tune, and A4L) failed to record any steps.
Data from defective trials have been excluded from all analyses.
3.2. Step counts
Bland–Altman limits of agreement demonstrated that the automated
step counts agreed relatively closely with the gold standard in the con-
trol group but differed markedly from the gold standard in patients
with RA.With the Activ4Life device, the variation between themeasure-
ments in patients with RA was comparable to that seen in controls (see
Fig. 2 and Table 2). Furthermore, in patientswith low step counts asmea-
sured by the video gold standard, the automated measures tended to
consistently further underestimate the number of steps taken. Converse-
ly, in RApatientswith higher step counts, i.e. nearer the levels seen in the
control group, the error in the automated measures decreased.
3.3. Temporal and spatial gait parameters
Analysis of temporal and spatial parameters recorded using the IDEEA
activity monitor revealed marked differences in agreement between the
measures across the two disease groups (see Fig. 3). The wider limits of
agreement indicate poorer agreement in the RA patients for all IDEEA de-
rived parameters except gait velocity, which showed slightly increased
levels of agreement. In contrast to the step counts, the level of agreement
Fig. 2. Regression based Bland–Altman plots illustrating agreement between different activity monitors and the gold standard. Solid line: mean agreement; dotted lines: 95% limits of
agreement.
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ship in which there were lower levels of agreement in patients with
higher levels of functional ability. Even in the control group however,
the IDEEA activity monitor underestimated both gait velocity and double
support time relative to the GAITRite gold standard.4. Discussion
This is the ﬁrst study to investigate the validity of a range of activity
monitors in patients with RA and a control group of healthy volunteers.
Although there was some variation between devices, the major ﬁnding
Table 2
Regression based Bland–Altman 95% limits of agreement and estimated mean differences for step counts of each of three automated measures.
Device
Step-N-Tune A4L IDEEA
RA patients
Variation in bias, per step −1.11x −0.38x −1.53x
Width of 95% LOA 169.74 52.90 225.00
Bias (95% LOA): 100 steps 110.59 (25.72 to 195.46) 6.12 (20.33 to 32.57) 127.84 (15.34 to 240.34)
150 steps 55.09 (−29.78 to 139.96) −12.88 (−39.33 to 13.57) 51.34 (−61.16 to 163.84)
200 steps −0.41 (−85.28 to 84.46) −31.88 (−58.33 to −5.43) −25.16 (137.66 to 87.34)
Controls
Variation in bias, per step 0.011x −0.13x −0.05x
Width of 95% LOA 22.64 44.16 61.52
Bias (95% LOA): 200 stepsa −6.51 (−17.83 to 4.81) −20.75 (−42.83 to 1.33) 21.47 (−9.29 to 52.23)
Bias = estimated mean difference between gold standard and test device; LoA = limits of agreement; x = mean of gold standard and test device.
a Estimates are only provided for controls at 200 steps because there were no observed data at lower step counts.
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to accurately record gait in this pathological sample. Whilst the devices
generally showed reasonable agreement with the gold standard in the
healthypopulation, the Step-N-Tune and IDEEAdevices performedpoorly
in patients with RA, whilst the A4L device showed only a slight decrease
in performance in patients with RA. The devices also demonstrated a
systematic decrease in their performance as RA patients' functional ability
fell further below the level of the control group.
This study provides useful information to help inform activity moni-
tor selection in future studies through direct comparison of devices. The
magnitude of error of some of the test devices was often very high in
comparison to the number of steps taken during the walk, and this was
particularly so in the RA group. If the limits of agreement are narrow,
bias need not necessarily be problematic as one may apply a conversion
factor to maintain consistency with the gold standard, however wide
limits of agreement render it difﬁcult to perform such a conversion
with any conﬁdence that the results would be accurate. Suchwide limits
of agreement as observed here call into question the validity of using
some devices in patients with RA. In the current study, the A4L device
had the highest level of agreement with the gold standard in patients
with RA, although larger long-term studies are still needed to investigate
the device's usability and durability in clinical populations outside the
laboratory. Furthermore, the additional temporal and spatial parameters
of gait measured by the IDEEA performed poorly in the RA group when
compared to a laboratory gold standard.
Although early studies in healthy volunteers conclude that the IDEEA
was 99% accurate in identifying types of activity in healthy volunteers,
concerns have been raised more recently about this device's ability to
measure temporal and spatial parameters (Mafﬁuletti et al., 2008;
Zhang et al., 2003). Mafﬁuletti et al. suggest that the device's inability
to measure acceleration in the transverse plane leads to large inaccura-
cies in step length estimates in patients with adducted or abducted feet
(Mafﬁuletti et al., 2008).With such deformity being common in patients
with RA, this may go some way to explaining the difference in the
device's performance between disease groups in the current study.
The number of activitymonitors available on themarket is increasing
and devices vary considerably in terms of their complexity and usability.
They range from simple pedometers and smartphone apps to novel nine
degrees of freedom devices that allow geographical tracking of subjects,
as well as complex multisensor devices that also record heart and GPS
data. This makes evidence based selection of activity monitors for
speciﬁc clinical populations ever more challenging. To facilitate device
comparison, future validation studies should seek to adopt common
experimental and analysis frameworks, as well as ensuring that patients'
functional ability is appropriately described. Furthermore, the growing
complexity of some devices may provide a barrier for use outside the
laboratory setting, particularly amongst patients with reduced dexterity
and this also warrants consideration.Although levels of agreement with the gold standard should be a
major considerationwhen selecting a device, othermore practical issues
such as price and usability alsowarrant consideration: it would be possi-
ble to buy up to 500 Step-N-Tune pedometers for each IDEEA activity
monitor purchased, and for simple step counts the Step-N-Tune pedom-
eter performed better in the control group. Some devices, such as the
IDEEA, require two episodes of face to face interaction between the
researcher and the participant in order calibrate the device and then to
download the data, whereas the A4L can transmit data without the
need for direct interaction. The visible step count and inexpensive nature
of the Step-N-Tune would enable participants to record step counts on a
piece of paper and return the device through the post.
All of the activity monitors used in this study rely on acceleration to
measure events, such as steps, during the gait cycle. Changes in acceler-
ation are either interpreted using signal processing algorithms in the
manufacturer's software, or via movement of a spring mounted lever
arm. The threshold for interpreting a change in acceleration as a step is
determined by the manufacturer during the device's development. The
magnitude of accelerations affecting the limbs and trunk during gait is,
in part, derived from a person's gait velocity and it has been widely
documented that patients with RA have reduced gait velocity (Turner
and Woodburn, 2008; Turner et al., 2003, 2006, 2008). Consequently, if
themanufacturers set the threshold using data fromhealthy populations
with normal gait, the device may underestimate activity levels in
patients with RA as was found in the current study. Similar ﬁndings
have also been reported in recent studies of older adults living in nursing
homeswithout RA (Cyarto et al., 2004). Furthermore, spring loaded lever
arm pedometers have been reported to miss steps in obese patients and
those taken at low frequencies (Feito et al., 2012; Tyo et al., 2011). A
potential further reﬁnement to help overcome this limitation might be
to enable the adjustment of the acceleration threshold required to record
a step so that activitymonitors could be calibrated to the particular char-
acteristics of patients exhibiting pathological gait patterns.
A strength of this studywas the concurrent testing of all activitymon-
itors during the same walk. This excluded the possibility of fatigue and
intra-subject variation between tests affecting the results. Furthermore,
the study used the same test procedure to evaluate the activity monitors
in a group of patients with RA and a normal control group. This suggests
that any change in the magnitude of error between groups was due to
differences in the characteristics of the group rather than systematic
error or researcher bias.
The current study investigated the ability of a range of activity
monitors in participants completing two tasks commonly performed in
daily living. As well as a period of walking, the study contained
transitions from walking to sitting, and from sitting to walking. A limita-
tion of the study was that it did not investigate the validity of the devices
during other common activities such as stair climbing, driving, or getting
in and out of bed. Future studies should investigate the ability of devices
Fig. 3. Regression based Bland–Altman plots for temporal and spatial gait parameters. Solid line: mean agreement; dotted lines: 95% limits of agreement.
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community dwelling populations can be interpreted with conﬁdence.
It was of concern that all devices apart from the gold standard failed
on at least one occasion during data capture. On each occasion, equip-
ment failure and loss of data were not evident until the end of the
walk meaning that no remedial action could be taken for that trial.Although this was problematic in our short periods of assessment, the
consequences of equipment failure when the devices are used over a
period of several days are likely to be magniﬁed. Within the current
study, equipment failure occurred more frequently in the RA group
and in somedevicesmore than others. Equipment failures of this nature
were unexpected however, so the study was not designed to measure
479M.R. Backhouse et al. / Clinical Biomechanics 28 (2013) 473–479failure rates, compare them between different devices, or between
disease groups. Appropriately designed and adequately powered
studies are needed to properly evaluate failure rates and determine
whether they are higher in different disease groups.
In conclusion, the activity monitors tested in the current study
performed reasonably well in healthy young volunteers but all except
the A4L showed a marked decrease in performance in patients with
RA. Furthermore, there was a systematic improvement in performance
as patient's functional ability increased towards the level of the control
group. Although activity monitors offer potential in patients with RA,
they must always be validated in target clinical populations.
Conﬂict of interest statement
All authors have declared that they have no ﬁnancial interests that
could create a potential conﬂict of interest or the appearance of a conﬂict
of interest with regard to the work.
References
Avina-Zubieta, J.A., Thomas, J., Sadatsafavi, M., Lehman, A.J., Lacaille, D., 2012. Risk of
incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of
observational studies. Ann. Rheum. Dis. 71, 1524–1529.
Bilek, L.D., Venema, D.M., Camp, K.L., Lyden, E.R., Meza, J.L., 2005. Evaluation of the human
activity proﬁle for use with persons with arthritis. Arthritis Rheum. 53, 756–763.
Bland, J.M., Altman, D.G., 1999. Measuring agreement in method comparison studies.
Stat. Methods Med. Res. 8, 135–160.
Cooney, J.K., Law, R.-J., Matschke, V., Lemmey, A.B., Moore, J.P., Ahmad, Y., et al., 2011.
Beneﬁts of exercise in rheumatoid arthritis. J. Aging Res. 2011, 681640.
Coughlin, S.S., 1990. Recall bias in epidemiologic studies. J. Clin. Epidemiol. 43, 87–91.
Cyarto, E.V., Myers, A.M., Tudor-Locke, C., 2004. Pedometer accuracy in nursing home
and community dwelling older adults. Med. Sci. Sports Exerc. 36, 205–209.
Durante, R., Ainsworth, B.E., 1996. The recall of physical activity: using a cognitive
model of the question–answering process. Med. Sci. Sports Exerc. 28, 1282.
Elkan, A.-C., Hakansson, N., Frostegard, J., Hafstrom, I., 2011. Low level of physical activity in
womenwith rheumatoid arthritis is associated with cardiovascular risk factors but not
with body fat mass—a cross sectional study. BMC Musculoskelet. Disord. 12, 13.
Feito, Y., Bassett, D.R., Thompson, D.L., 2012. Evaluation of activity monitors in controlled
and free-living environments. Med. Sci. Sports Exerc. 44, 733–741.Helliwell, P.S., Woodburn, J., Redmond, A.C., Turner, D.E., Davies, H.J., 2007. The Foot
and Ankle in Rheumatoid Arthritis: A Comprehensive Guide. Churchill Livingstone,
London.
Jacobs, D.R., Ainsworth, B.E., Hartman, T.J., Arthur, L., 1993. A simultaneous evaluation of 10
commonly used physical activity questionnaires. Med. Sci. Sports Exerc. 25, 81–91.
Kirkwood, B.R., Sterne, A.C., 2006. Essential Medical Statistics. Blackwell Publishing, Oxford.
Kriska, A.M., Caspersen, C.J., 1997. Introduction to a collection of physcial question-
naires for health related research. Med. Sci. Sports Exerc. 29, S5–S9.
Lee, I.M., Blair, S., Manson, J., Paffenbarger, R.S.J., 2009. Epidemiologic Methods in Physical
Activity Studies. Oxford University Press, New York.
Mafﬁuletti, N.A., Gorelick, M., Kramers-De Quervain, I., Bizzini, M., Munzinger, J.P.,
Tomasetti, S., et al., 2008. Concurrent validity and intrasession reliability of the
IDEEA accelerometry system for the quantiﬁcation of spatiotemporal gait parameters.
Gait Posture 27, 160–163.
Menz, H.B., Latt, M.D., Tiedemann, A., Mun San Kwan, M., Lord, S.R., 2004. Reliability of
the GAITRite walkway system for the quantiﬁcation of temporo-spatial parameters
of gait in young and older people. Gait Posture 20, 20–25.
Rome, K., 2005. Within-day reliability of temporal–spatial gait parameters associated
with rheumatoid arthritic feet. Musculoskeletal Care 3, 17–23.
Semple, R., Turner, D.E., Helliwell, P.S., Woodburn, J., 2007. Regionalised centre of pressure
analysis in patients with rheumatoid arthritis. Clin. Biomech. 22, 127–129.
Turner, D.E., Woodburn, J., 2008. Characterising the clinical and biomechanical features
of severely deformed feet in rheumatoid arthritis. Gait Posture 28, 574–580.
Turner, D., Woodburn, J., Helliwell, P.S., Cornwall, M.W., Emery, P., 2003. Pes planovalgus in
RA: a descriptive and analytical study of foot function determined by gait analysis.
Musculoskeletal Care 1, 21–33.
Turner, D.E., Helliwell, P., Emery, P., Woodburn, J., 2006. The impact of rheumatoid
arthritis on foot function in the early stages of disease: a clinical case series.
BMC Musculoskelet. Disord. 7, 102–110.
Turner, D.E., Helliwell, P.S., Siegel, K.L., Woodburn, J., 2008. Biomechanics of the foot in
rheumatoid arthritis: identifying abnormal function and the factors associated
with localised disease ‘impact’. Clin. Biomech. 23, 93–100.
Tyo, B.M., Fitzhugh, E.C., Bassett JR., D.R., John, D., Feito, Y., Thompson, D.L., 2011. Effects
of body mass index and step rate on pedometer error in a free-living environment.
Med. Sci. Sports Exerc. 43, 350.
Van Den Berg, M.H., De Boer, I.G., Le Cessie, S., Breedveld, F.C., Vliet Vlieland, T.P.M.,
2007. Are patients with rheumatoid arthritis less physically active than the general
population? JCR: J. Clin. Rheumatol. 13, 181–186.
Zhang, K., Werner, P., Sun, M., Pi-Sunyer, F.X., Boozer, C.N., Zhang, K., et al., 2003. Measure-
ment of human daily physical activity. Obes. Res. 11, 33–40.
Zhang, K., Pi-Sunyer, F.X., Boozer, C.N., 2004. Improving energy expenditure estimation
for physical activity. Med. Sci. Sports Exerc. 36, 883–889.
